Sol-Gel Technologies (SLGL) Accumulated Depreciation & Amortization (2016 - 2025)
Sol-Gel Technologies (SLGL) reported Accumulated Depreciation & Amortization of $109000.0 for Q4 2025, down 53.22% year-over-year from $233000.0 in Q4 2024, and down 53.22% quarter-over-quarter from $233000.0 in Q4 2024.
Sol-Gel Technologies (SLGL) Accumulated Depreciation & Amortization (2016 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has 10 years of Accumulated Depreciation & Amortization data on file, last reported at $109000.0 in Q4 2025.
- Accumulated Depreciation & Amortization for Q4 2025 came in at $109000.0, down 53.22% year-over-year; the trailing twelve-month figure through Dec 2025 was $109000.0 (down 53.22% YoY), and the FY2025 annual result was $109000.0, down 53.22% from the prior year.
- Accumulated Depreciation & Amortization fell to $109000.0 in Q4 2025 per SLGL's latest filing, from $233000.0 in the prior quarter.
- Over five years, Accumulated Depreciation & Amortization peaked at $880000.0 in Q4 2021 and troughed at $109000.0 in Q4 2025.
- A 5-year average of $425200.0 and a median of $342000.0 in 2023 frame the typical range for Accumulated Depreciation & Amortization.
- The sharpest annual moves came in 2021 and 2025: Accumulated Depreciation & Amortization slipped 6.98% in 2021, then tumbled 53.22% in 2025.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $880000.0 in 2021, then slumped by 36.14% to $562000.0 in 2022, then sank by 39.15% to $342000.0 in 2023, then plunged by 31.87% to $233000.0 in 2024, then plunged by 53.22% to $109000.0 in 2025.
- Business Quant data shows SLGL's Accumulated Depreciation & Amortization at $109000.0 in Q4 2025, $233000.0 in Q4 2024, and $342000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Sol-Gel Technologies | 223.21 Mn | 213.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 109,000.00 |
| Dec 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Dec 31, 2023 | 342,000.00 |
| Dec 31, 2023 | 342,000.00 |
| Dec 31, 2022 | 562,000.00 |
| Dec 31, 2022 | 562,000.00 |
| Dec 31, 2021 | 880,000.00 |
| Dec 31, 2021 | 880,000.00 |
| Dec 31, 2020 | 946,000.00 |
| Dec 31, 2020 | 946,000.00 |
| Dec 31, 2019 | 887,000.00 |
| Dec 31, 2019 | 887,000.00 |
| Dec 31, 2018 | 762,000.00 |
| Dec 31, 2018 | 762,000.00 |
| Dec 31, 2017 | 471,000.00 |
| Dec 31, 2017 | 471,000.00 |
| Dec 31, 2016 | 359,000.00 |
| Dec 31, 2016 | 359,000.00 |